We Guide Biotech Through The Big Moments

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

Clasp Therapeutics Presents Comprehensive Preclinical Data Validating First-in-Class Precision T Cell Engager Against p53 Mutant Solid Tumors at SITC Annual Meeting

Parabilis Medicines™ – Formerly FogPharma – Announces New Company Name and Unveils AI- and Physics-Based Discovery Platform

Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round

Booster Therapeutics Launches to Pioneer New Class of Proteasome Activator Medicines for the Treatment of a Range of Complex Diseases

Meet the BostInno 2024 Fire Awards honorees

The 2024 PharmaVoice 100: Li Peng

Endpoints News Announces the 2024 Winners of the Endpoints 11 Awards, Highlighting Biotech’s Most Promising Startups

Orbis Medicines and Vivtex Form Research & Exclusive Licensing Collaboration to Support Orbis Development of Next-Generation Orally Dosable ‘nCycles’

AIRNA Raises Oversubscribed $60 Million Financing to Advance New Class of RNA Editing Medicines and Progress Best-in-Class AATD Program into the Clinic

Vividion Therapeutics to Expand with New Global Research and Development Center

SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline

Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)

Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform

Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above